11月25日，振东制药涨5.31%，截至发稿，报6.74元/股，成交1.37亿元，换手率2.09%，总市值66.88亿 元。 财通资管医疗保健混合A（018484）基金经理为王鑫园。 截至发稿，王鑫园累计任职时间16天，现任基金资产总规模3.59亿元，任职期间最佳基金回报-2.32%， 任职期间最差基金回报-4.78%。 从基金十大重仓股角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 数据显示，财通证券资管旗下1只基金重仓振东制药。财通资管医疗保健混合A（018484）三季度持有 股数80万股，占基金净值比例为6.04%，位居第九大重仓股。根据测算，今日浮盈赚取约27.2万元。 责任编辑：小浪快报 财通资管医疗保健混合A（018484）成立日期2023年8月3日，最新规模6430.06万。今年以来收益 20.51%，同类排名3452/8136；近一年收益20.63%，同类排名3641/8058；成立以来收益6.82%。 资料显示，山西振东制药股份有限公司位于山西省长 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2025年11月15日，财通资管医疗保健混合（018484）发布公告，易小金不再担任该基金 基金经理，离任日期为2025年11月15日，变更后财通资管医疗保健混合（018484）的基金经理为王鑫 园。截止2025年11月14日，财通资管医疗保健混合净值为1.1430，较上一日上涨0.08%，近一年上涨 23.93%。 ...

Group 1 - The core point of the news is that Selys Medical has seen a stock price increase of 5.89%, reaching 26.24 CNY per share, with a total market capitalization of 5.515 billion CNY [1] - Selys Medical, established on February 23, 2004, and listed on October 31, 2016, is primarily engaged in medical testing, marketing services, and the development, production, and sales of in vitro diagnostic products [1] - The revenue composition of Selys Medical includes 39.91% from IVD business, 38.01% from SPD business, and 22.08% from pure sales [1] Group 2 - According to data, one fund under Caitong Securities Asset Management holds a significant position in Selys Medical, with 200,000 shares, representing 5.72% of the fund's net value, ranking as the tenth largest holding [2] - Caitong Asset Management Healthcare Mixed A Fund (018484) has achieved a year-to-date return of 26.65% and a one-year return of 24.44%, ranking 3236 out of 8150 and 3250 out of 8043 respectively [2] - The fund was established on August 3, 2023, with a current scale of 64.3006 million CNY, and has generated an estimated floating profit of approximately 292,000 CNY today [2]

Group 1 - The core point of the news is that Selys Medical experienced a stock price increase of 5.24%, reaching 25.10 CNY per share, with a trading volume of 400 million CNY and a turnover rate of 7.74%, resulting in a total market capitalization of 5.275 billion CNY [1] - Selys Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, established on February 23, 2004, and listed on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and research, production, and sales of self-developed in vitro diagnostic products [1] - The revenue composition of Selys Medical is as follows: IVD business accounts for 39.91%, SPD business for 38.01%, and pure sales for 22.08% [1] Group 2 - From the perspective of fund holdings, one fund under Caitong Securities Asset Management has a significant position in Selys Medical. The Caitong Asset Management Healthcare Mixed A Fund (018484) held 200,000 shares in the third quarter, representing 5.72% of the fund's net value, ranking as the tenth largest holding [2] - The Caitong Asset Management Healthcare Mixed A Fund (018484) was established on August 3, 2023, with a latest scale of 64.306 million CNY. Year-to-date returns are 26.17%, ranking 3675 out of 8154 in its category; the one-year return is 25.68%, ranking 3563 out of 8046; and since inception, the return is 11.84% [2]

Core Insights - The AI Fund Caizheng Asset Management Healthcare Mixed A (018484) reported a profit of 24.79 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1341 yuan [2] - The fund's net value growth rate for the reporting period was 12.31%, and the fund size reached 131 million yuan by the end of Q2 [2][14] - The fund focuses on long-term investments in pharmaceutical and healthcare stocks, with a unit net value of 1.2 yuan as of July 18 [2] Performance Metrics - As of July 18, the fund's one-year cumulative net value growth rate was 40.05%, ranking 68 out of 133 comparable funds [3] - The fund's three-month and six-month cumulative net value growth rates were 27.15% and 38.72%, ranking 71 out of 138 and 73 out of 138 respectively [3] - The fund has maintained an average stock position of 85.93% since inception, with a peak of 92.29% at the end of Q1 2024 [13] Risk and Return Analysis - The fund's Sharpe ratio since inception is 0.2868, indicating a moderate risk-adjusted return [7] - The maximum drawdown since inception is 29.68%, with the largest quarterly drawdown occurring in Q1 2024 at 21.64% [10] Investment Strategy - The fund manager, Yi Xiaojin, emphasizes identifying investment targets that can benefit from the aging economy and domestic demand evolution, focusing on sectors such as innovative drugs, medical devices, and pharmacies [2] - The fund aims to invest in companies that are actively embracing international expansion, particularly in medical consumables, raw materials, and innovative medical devices [2] - The fund holds a concentrated portfolio, with the top ten holdings including companies like Rejing Biology, Zhaoyan New Drug, and WuXi AppTec [17]